Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

Cancer immunotherapies utilizing genetically engineered T cells have emerged as powerful personalized therapeutic agents showing dramatic preclinical and clinical results, particularly in hematological malignancies. Ectopically expressed chimeric antigen receptors (CARs) reprogram immune cells to ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Celichowski, Piotr, Turi, Marcello, Charvátová, Sandra, Radhakrishnan, Dhwani, Feizi, Neda, Chyra, Zuzana, Šimíček, Michal, Jelínek, Tomáš, Bago, Juli Rodriguez, Hájek, Roman, Hrdinka, Matouš
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015723/
https://www.ncbi.nlm.nih.gov/pubmed/36922828
http://dx.doi.org/10.1186/s12967-023-04041-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015723/
https://www.ncbi.nlm.nih.gov/pubmed/36922828
http://dx.doi.org/10.1186/s12967-023-04041-6

Ejemplares similares